Clinical Trial Highlights

• Long-term Canagliflozin is Efficacious and Generally Well Tolerated in Older Patients
• Combined Saxagliptin and Dapagliflozin Reduce Blood Glucose Levels in T2DM Patients
• Combining Empagliflozin and Linagliptin with Metformin Reduces HbA_1c in Patients with T2DM
• Empagliflozin Superior to Glimepiride as Second-line Treatment in T2DM
• LIRA-ADD2BASAL: Liraglutide Added to Basal Insulin Analogs Improves Glycemic Control
• Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM
• Dulaglutide Reduces HbA_1c More Than Glargine When Used in Combination with Prandial Insulin
• Structured Education and Appropriate Pharmacologic Intervention in a Day Clinic Improves Glycemic Control in Adult Patients with Diabetes
• Group Education Courses in Recently Diagnosed Patients with T2DM
• Exenatide Increases Glucose Uptake in Brain Areas Involved in Glucose Homeostasis and Food Intake
• SCALE Diabetes: Continually Dosed Liraglutide May Aid Weight Loss in T2DM
• Patient Involvement in Diabetes Care: Greek Study of Decision Aids Inconclusive
• IDegLira Offers Advantages over IDeg and Liraglutide in T2DM: DUAL I Results
• Once Weekly Exenatide is Safe and Effective for Long-term T2DM Treatment
• GLUCO-CABG: No Reduction in Perioperative Complications to Cardiac Surgery with Intensive Control of Hyperglycemia
• Effects of PDE-5 Inhibition in Patients with T2DM
• Novel Once-Weekly Omarigliptin as Effective and Well Tolerated as Once-Daily Sitagliptin in Japanese Patients